Arvelle Therapeutics International
Latest round
- Series A
Last raised
- May 2020
Total raised
- $217M
Investors
- 7
About Arvelle Therapeutics International
Arvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing innovative therapies for patients with central nervous system disorders.Arvelle Therapeutics International GmbH specializes in the development of treatments for central nervous system conditions. Founded in 2019 in Zug, Switzerland, the company has undergone a significant transition in its corporate strategy. In January 2021, Arvelle was acquired by Angelini Pharmaceuticals for USD 610 mn in cash, with potential for an additional USD 350 mn contingent on revenue milestones. This acquisition highlights the strategic value of Arvelle's portfolio, which aligns with Angelini's therapeutic interests.Arvelle Therapeutics International GmbH focuses on developing advanced therapeutics aimed at treating central nervous system disorders. Their lead product is designed to improve the quality of life for patients suffering from epilepsy and related conditions, offering a novel mechanism of action compared to existing treatments. The company aims to introduce new therapies for central nervous system disorders and is exploring opportunities for market expansion throughout Europe and North America. The strategic direction focuses on utilizing the resources from the TRADE SALE to accelerate research and development efforts, with anticipated launches in the upcoming years, further solidifying its position in the biopharmaceutical landscape.
Who invested in Arvelle Therapeutics International
7 investors across 2 rounds
See all investors in Arvelle Therapeutics International
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Arvelle Therapeutics International
Who invested in Arvelle Therapeutics International?
Arvelle Therapeutics International has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Arvelle Therapeutics International raised?
Arvelle Therapeutics International has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Arvelle Therapeutics International last raise money?
Arvelle Therapeutics International's most recent round on record is a Series A, in May 2020.
What does Arvelle Therapeutics International do?
Arvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing innovative therapies for patients with central nervous system disorders.
Where is Arvelle Therapeutics International headquartered?
Arvelle Therapeutics International is headquartered in Zug, Switzerland.
Which VCs invest in companies like Arvelle Therapeutics International?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Arvelle Therapeutics International's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Arvelle Therapeutics International? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.